Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.
|Articles|April 30, 2012
In Hopeful Sign, Health Spending Is Flattening Out
Advertisement
The growth of health spending has slowed substantially in the last few years, surprising experts and offering some fuel for optimism about the federal government’s long-term fiscal performance.
recession
Much of the slowdown is because of the , and thus not unexpected, health experts say. But some of it seems to be attributable to changing behavior by consumers and providers of health care — meaning that the lower rates of growth might persist even as the economy picks up.
Read the full story:
Source: The New York Times
Advertisement
Related to this article
A clinical-note analysis of more than 1000 patients found rising off-label BPC-157 use for pain and healing, with outcomes unproven.
Frailty, but not HIV serostatus, is tied to more severe lower urinary tract symptoms in adults with and at risk for HIV, a cross-sectional study finds.
About one quarter of patients with overactive bladder were taking their initial oral regimen at nearly 3 years, yet most reported symptom improvement.
Claims data show evidence of HIV virus in 5 of 2913 long-acting cabotegravir users and higher adherence vs oral therapy.
Mirabegron was not tied to higher obesity-related neoplasm risk vs antimuscarinics in overactive bladder, but all-cause mortality was higher.
Experts at AMCP Nexus say biosimilar launches should prompt payers to revisit step therapy and measure value beyond market share.
Telehealth surpasses out-of-state travel for abortion care in total-ban states in 2025, and a second study suggests telehealth and clinic patients differ.
Advertisement
Advertisement
Trending on AJMC
1
Retatrutide Tops Semaglutide on A1C, Weight in Head-to-Head Trial
2
Biosimilar Entry Should Trigger a Fresh Look at Biologic Access
3
Telehealth Overtakes Travel in States With Total Abortion Bans
4
New Data Link Cabotegravir PrEP to Few HIV Cases, Higher Adherence
5